Immunome Inc.

IMNM | NASDAQ

Price Alert Chart Builder DCF Calculator

$25.07

+$1.10 (+4.59%)

At close: Sep 21, 2026, 4:00 PM ET

$25.07

$0 (0.00%)

Pre-market: Sep 22, 2026, 7:24 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
ABCL AbCellera Biologics	N/A
BHVN Biohaven	N/A
CLDX Celldex Therapeutics	N/A
MAZE Maze Therapeutics	N/A
NTLA Intellia Therapeutics	N/A
PHVS Pharvaris	N/A
SYRE Spyre Therapeutics	N/A
UPB Upstream Bio	N/A
VERA Vera Therapeutics	N/A
ZBIO Zenas BioPharma	N/A

Dividend Rankings ➞

Recent News

14 days ago / businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 days ago / businesswire.com
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
1 month ago / marketbeat.com
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
1 month ago / globenewswire.com
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
1 month ago / seekingalpha.com
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
2 months ago / businesswire.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
2 months ago / fool.com
What This Immunome Sale Means a Day Before a Big FDA Milestone
2 months ago / zacks.com
Immunome Stock Up 32% in a Month: Here's What You Should Know
3 months ago / businesswire.com
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
3 months ago / gurufocus.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors